- Home
- OSTX vs MRSN Comparison
OSTX vs MRSN Comparison
Compare OSTX & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OSTX
- MRSN
- Stock Information
- Founded
- OSTX 2018
- MRSN 2001
- Country
- OSTX United States
- MRSN United States
- Employees
- OSTX N/A
- MRSN N/A
- Industry
- OSTX
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- OSTX
- MRSN Health Care
- Exchange
- OSTX NYSE
- MRSN Nasdaq
- Market Cap
- OSTX 43.0M
- MRSN 40.7M
- IPO Year
- OSTX 2024
- MRSN 2017
- Fundamental
- Price
- OSTX $1.81
- MRSN $0.36
- Analyst Decision
- OSTX Strong Buy
- MRSN Strong Buy
- Analyst Count
- OSTX 3
- MRSN 5
- Target Price
- OSTX $18.00
- MRSN $5.75
- AVG Volume (30 Days)
- OSTX 302.3K
- MRSN 2.3M
- Earning Date
- OSTX 08-14-2025
- MRSN 08-12-2025
- Dividend Yield
- OSTX N/A
- MRSN N/A
- EPS Growth
- OSTX N/A
- MRSN N/A
- EPS
- OSTX N/A
- MRSN N/A
- Revenue
- OSTX N/A
- MRSN $34,006,000.00
- Revenue This Year
- OSTX N/A
- MRSN N/A
- Revenue Next Year
- OSTX N/A
- MRSN $1.30
- P/E Ratio
- OSTX N/A
- MRSN N/A
- Revenue Growth
- OSTX N/A
- MRSN N/A
- 52 Week Low
- OSTX $1.12
- MRSN $0.26
- 52 Week High
- OSTX $7.00
- MRSN $2.83
- Technical
- Relative Strength Index (RSI)
- OSTX N/A
- MRSN 46.82
- Support Level
- OSTX N/A
- MRSN $0.35
- Resistance Level
- OSTX N/A
- MRSN $0.39
- Average True Range (ATR)
- OSTX 0.00
- MRSN 0.03
- MACD
- OSTX 0.00
- MRSN -0.00
- Stochastic Oscillator
- OSTX 0.00
- MRSN 12.30
About OSTX OS THERAPIES INCORPORATED
OS Therapies Inc is a clinical stage biopharmaceutical company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. The companys mission is to address the need for new treatments in cancers of the bone in children and young adults.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.